Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study
- 1 June 2001
- journal article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 221 (1-2) , 175-186
- https://doi.org/10.1016/s0378-5173(01)00684-6
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic MalignanciesJournal of Clinical Oncology, 2000
- Immunotoxins in cancer therapyCurrent Opinion in Immunology, 1999
- A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's LymphomaBlood, 1997
- Immunotoxins in the therapy of cancer: From bench to clinicPharmacology & Therapeutics, 1994
- A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapyBlood, 1993
- The GLP large scale preparation of immunotoxins containing deglycosylated ricin A chain and a hindered disulfide bondJournal of Immunological Methods, 1991
- Distribution of endocytosed molecules to intracellular acidic environments correlates with immunotoxin activityInternational Journal of Cancer, 1990
- Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid- resistant acute graft-versus-host diseaseBlood, 1990
- An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeysCancer Immunology, Immunotherapy, 1989
- Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagentBiochemical Journal, 1978